



Resolution n°7-2024-e

Cost Extension for the Project “Long-acting injectable formulation of ivermectin as a new vector control tool to reduce malaria transmission” (IMPACT)

Recalling Unitaid Board Resolution n°4-2020-e in which the Board authorized the Executive Director to commit up to US\$ 6,358,125 for the project entitled “Long-acting injectable formulation of ivermectin as a new vector control tool to reduce malaria transmission” (the “Project”) to be implemented by MedinCell SA for a 3-year period;

Noting that in 2022 and 2023, the Secretariat approved two no-cost extensions for the Project of 9 and 3 months respectively, together ending on 31 March 2024;

Taking into account the assessment by the PRC and the Secretariat’s recommendations, the Board authorizes the Executive Director, subject to the availability of funds, to commit additional funding of up to US\$ 5,980,703 for the Project and to extend the duration of funding for the Project for a further 33 months up to 31 December 2026.

The additional funding and extension to the Project duration are conditional upon signature of an amendment to the legal agreement between Unitaid and MedinCell.

A handwritten signature in blue ink that reads "Marisol Touraine". Below the signature is a horizontal line.

Marisol Touraine
Chair of the Executive Board

Date: 29 January 2024